Cerenome Adds Florida Blue In-Network Deal, First to Cover Molecular Profile Tests
CNSY is trading near its 52-week low of $1.485 (9.8% above the low).
Summary
Cerenome's CNSide Diagnostics signed an in-network agreement with Florida Blue effective October 1, 2026, covering both the CNSide CSF Tumor Cell Enumeration test and the new CNSide CSF Molecular Profile tests. This is the first payer agreement to include molecular profiling, expanding the commercial footprint by approximately 6 million covered lives to a total of about 164 million. The deal follows similar agreements with HCSC and Blue Cross Blue Shield of Michigan announced in August and September, showing steady execution of the national reimbursement strategy. For a company with a $12.4 million market cap and $8.6 million in cash, each payer win is material to revenue potential. The molecular profile tests are slated for commercial launch in October 2026, so this agreement provides immediate contracted reimbursement as they roll out.
At the time of this announcement, CNSY was trading at $1.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.4M. The 52-week trading range was $1.49 to $21.48. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.